Compare
BioRestorative Therapies, Inc. vs Mangoceuticals, Inc. vs Charming Medical Ltd vs Cryo Cell International Inc
| Latest fiscal year | BioRestorative Therapies, Inc. BRTX | Mangoceuticals, Inc. MGRX | Charming Medical Ltd MCTA | Cryo Cell International Inc CCEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-03-31 | 2025-11-30 |
| Revenue | $359.7K | $456.0K | $4.81M | $31.57M |
| Revenue growth (YoY) | -10.3% | -26.0% | -22.7% | -1.3% |
| Gross margin | 93.4% | 54.9% | n/a | 76.6% (computed) |
| Operating margin | n/m | n/m | -0.6% | 1.5% |
| Net margin | n/m | n/m | -0.5% | -7.7% |
| Net income | -$14.24M | -$20.64M | -$22.6K | -$2.43M |
| EPS (Diluted) | -$1.58 | -$2.17 | $0.00 | -$0.30 |
| Operating cash flow | -$10.79M | -$5.85M | -$1.22M | $5.48M |
| Free cash flow | -$10.91M | n/a | -$1.56M | $5.25M |
| Cash & equivalents | $1.51M | $1.49M | $4.70M | $319.0K |
| Total assets | $4.08M | $16.09M | $9.87M | $61.73M |
| Total liabilities | n/a | $890.6K | $4.69M | $80.33M |
| Shareholders' equity | $356.7K | $15.20M | $5.18M | -$18.61M |
| Return on year-end equity | n/m | -135.8% | -0.4% | n/a |
| Shares outstanding | 8.88M | 15.89M | n/a | 8.06M |
Revenue, most recent five fiscal years
| Fiscal year | BioRestorative Therapies, Inc. | Mangoceuticals, Inc. | Charming Medical Ltd | Cryo Cell International Inc |
|---|---|---|---|---|
| Latest | $359.7K Ended 2025-12-31 | $456.0K Ended 2025-12-31 | $4.81M Ended 2026-03-31 | $31.57M Ended 2025-11-30 |
| 1 year earlier | $401.0K Ended 2024-12-31 | $615.9K Ended 2024-12-31 | $6.22M Ended 2025-03-31 | $31.99M Ended 2024-11-30 |
| 2 years earlier | $145.8K Ended 2023-12-31 | $731.5K Ended 2023-12-31 | $6.02M Ended 2024-03-31 | $31.34M Ended 2023-11-30 |
| 3 years earlier | $119.8K Ended 2022-12-31 | $8.9K Ended 2022-12-31 | n/a | $30.34M Ended 2022-11-30 |
| 4 years earlier | $46.0K Ended 2021-12-31 | n/a | n/a | $28.88M Ended 2021-11-30 |